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Abstract
Functional magnetic resonance imaging (fMRI) successfully disentangled neuronal pathophysiology of major depression
(MD), but only a few fMRI studies have investigated correlates and predictors of remission. Moreover, most studies
have used clinical outcome parameters from two time points, which do not optimally depict differential response
times. Therefore, we aimed to detect neuronal correlates of response and remission in an antidepressant treatment study with
7 T fMRI, potentially harnessing advances in detection power and spatial specificity. Moreover, we modeled
outcome parameters from multiple study visits during a 12-week antidepressant fMRI study in 26 acute (aMD) patients
compared to 36 stable remitted (rMD) patients and 33 healthy control subjects (HC). During an electrical painful stimulation
task, significantly higher baseline activity in aMD compared to HC and rMD in the medial thalamic nuclei of
the pulvinar was detected (p= 0.004, FWE-corrected), which was reduced by treatment. Moreover, clinical response
followed a sigmoid function with a plateau phase in the beginning, a rapid decline and a further plateau at treatment end.
By modeling the dynamic speed of response with fMRI-data, perigenual anterior cingulate activity after treatment
was significantly associated with antidepressant response (p< 0.001, FWE-corrected). Temporoparietal junction (TPJ)
baseline activity significantly predicted non-remission after 2 antidepressant trials (p= 0.005, FWE-corrected). The results
underline the importance of the medial thalamus, attention networks in MD and antidepressant treatment. Moreover, by
using a sigmoid model, this study provides a novel method to analyze the dynamic nature of response and remission for
future trials.
Introduction
First-line medication of major depression (MD) consists of
antidepressant treatment with selective serotonin-reuptake
inhibitors (SSRIs) [1, 2]. After non-responsive treatment in
the first trial a second trial with an antidepressant with a
differential mechanism of action such as a serotonin-
noradrenaline reuptake inhibitor (SNRI) is often performed.
After both sequential treatments in total about 30–60%
achieve remission, leaving about 70–40% of all patients
depressed [3, 4]. For medication-naive patients, estimation
of future response and remission remains open to clinical
judgments [5]. To obtain biological markers of treatment
effects, studies investigated blood-oxygen-level dependent
(BOLD) signal changes upon antidepressant treatment with
fMRI. In the beginning, most of these studies investigated
correlates of response [6], only recently fMRI-studies
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focused on remission [7]. While neurobiological response
markers may be of interest for drug development or clinical
research, predictive markers of remission have the potential
to be clinically applicable, by allowing patients and physi-
cians to anticipate who will maximally improve before
treatment.
A recent fMRI antidepressant trial investigated predictive
markers of remission [8]. In this study, dorsolateral pre-
frontal cortex (dlPFC) activity in a Go/NoGo response
inhibition task significantly predicted remission, whereas
higher post-treatment dlPFC activity was associated with
non-remission. A prior investigation failed to detect base-
line differences between remitter and non-remitter using a
Stroop Color-Word paradigm [9]. These previous fMRI
studies on remission to antidepressant therapy applied lower
field strengths at 3 T [8] and 1.5 T [9].
Other neurobiological substrates of depression are the
anterior and medial cingulate cortex as well as the insula.
Areas that can be activated by various salient stimuli like
electrical painful stimulation [10]. In a pilot study we showed
that 7 T fMRI had advantageous BOLD responses to trans-
cutaneous electrical stimulation as compared to 3 T in brain
areas associated with pain processing [11]. Based on the
neuronal activation pattern of painful stimuli and our pilot
study, we conducted an antidepressant treatment study at 7 T
with the aim of assessing treatment effects in order to
investigate correlates of response and discover predictors of
remission. Furthermore, we aimed to improve response
assessment by modeling clinical outcome parameters from all
available study visits. Applying dynamic response modeling
we aim to predict response and remission in an explanatory
whole-brain approach, without limitation to a priori defined
regions of interest. Based on the previous study [10] and our
pilot study, we hypothesized that anterior and midcingulate
cortex as well as insular, prefrontal and basal ganglia func-
tionality would exhibit significant treatment effects.
Methods
Participants and treatment
All participants gave oral and written informed consent to
the study protocol. Subjects were compensated financially
for their participation. The study protocol and all study
related procedures were approved by the Ethics Committee
of the Medical University (EK 103/2011) of Vienna and
registered at clinicaltrials.gov (NCT01477203). Study
duration was from November 2011 to September 2016. For
inclusion and exclusion criteria see supplementary methods.
All medication free acute (aMD) patients underwent an
open label, flexible dose, unblinded, but standardized anti-
depressant treatment for 12 weeks with control visits with
possible dosage adjustment every two weeks. fMRI-1 was
at week 0 and fMRI-2 was scheduled 12 weeks later. As
first line treatment, all aMD patients received escitalopram
oxalate for six weeks. A starting dosage of 5 mg was
allowed for better tolerance for a maximum of 5 days,
afterwards flexible escitalopram dosages between 10–20 mg
were given according to clinical judgment by study psy-
chiatrists. Down-titration to 15 or 10 mg was allowed, if 20
mg were not tolerated due to side effects.
If acute patients did not respond to the first-line anti-
depressant after 6 weeks, defined by at least 50% Hamilton
Depression Rating Scale (HAM-D24) reduction compared to
first visit, they were switched to a second trial with venla-
faxine extended release 75–150 mg or mirtazapine 30–60
mg, if venlafaxine was not tolerated. If venlafaxine or
mirtazapine was previously not tolerated, escitalopram
10–20 mg was allowed to continue, even if patients did not
respond after 6 weeks. The second trial treatment was
administered for another six weeks with control visits until
fMRI-2 (v1= inclusion, v2= fMRI 1 and week 0 of treat-
ment, v3=week 2, v4=week 4, v5=week 6, v6=week
8, v7=week 12 and fMRI-2, v8= follow up). All three
groups were measured 12 weeks apart for fMRI-1 and
fMRI-2.
Outcome parameters
All patients were assessed by psychiatrists with at least 3
years of experience in clinical psychological testing at every
visit with HAM-D24, Hamilton Anxiety Rating Scale
(HAM-A), Beck Depression Index (BDI), and Clinical
Global Impression Scale (CGI). Response (−50% HAM-
D24 compared to visit 1) was assessed at every visit.
Remission was assessed at visits 5 (week 6) and 7 (=
fMRI-2, week 12) and defined as <8 on the HAM-D24
scale, which was chosen as a conservative cutoff to mini-
mize residual symptoms. Healthy controls and remitted
(rMD) subjects were tested with the same questionnaires at
baseline visit, fMRI-1 and fMRI-2, as well as at end-of-
study examination.
fMRI analyses
The entire pain paradigm and image preprocessing are
detailed in the supplementary material and in the pilot stu-
dies [11, 12]. Single-subject analysis was conducted using
the General Linear Model approach as implemented in
SPM12 (http://www.fil.ion.ucl.ac.uk/spm/). For each possi-
ble anticipation and stimulation condition, a regressor was
modeled. Nuisance regressors included 6 realignment para-
meters, 4 white matter, and 1 ventricles confounding signal.
To test group differences and hence treatment effects
between fMRI scans a 3× 2 repeated measures ANOVA
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(rmANOVA) was calculated in SPM12 with group as
between-subject and scan as within-subject factor contrast-
ing pain vs. no-pain and expect vs. unsure conditions. This
analysis was corrected for sex, age, and an index for the
individually calibrated pain stimulation intensity (1–10) at
the scan day (= painful intensity–non painful intensity).
Post-hoc t-tests between every group and scan were
performed.
Based on visual inspection of HAM-D24 scores across all
8 visits, a sigmoid course was suggested. Therefore,
response over visits was fitted in a sigmoidal model with
scaling and offset parameters for time between visits and
HAM-D24 scores with following parameters:
σ tð Þ ¼ a
1þ ebtþc þ d
whereby a represented the amplitude between highest and
lowest HAM-D24 score (i.e., maximum change in HAM-D24
score), b was the time scaling, i.e., the speed of transition
between upper and lower plateau phase, c modeled the tem-
poral shift of the curve, and d was the lowest HAM-D24 value
allowed. The parameter b was most important for the current
study since it reflects the dynamic change of HAM-D24 score
over time (i.e., the speed how fast a patient experiences
changes in HAM-D24 score). If model fitting with all available
data points lead to implausible results (e.g., reduction of the
transition between the plateau phases to a step function),
responsible outliers were identified and removed (maximum
one per subject). Fitting was accomplished using the
MATLAB “fit” function (2013b, The MathWorks, Inc.,
Natick, Massachusetts, United States, Curve Fitting Toolbox
3.4.) with the “least absolute residuals” method.
To model the dynamic response to antidepressant treat-
ment over 12 weeks in the group of currently depressed
patients, the speed of transition values (b), i.e., the slopes of
the dynamic response function, were used in a regression
model with pain, no-pain, expect and unsure contrasts in the
pain paradigm in SPM 12 correcting for sex, age, and pain
stimulation indices. Imaging results were correlated with
escitalopram or venlafaxine plasma values (supplementary
methods).
Finally, we assessed predictability or correlates of remis-
sion between remitted and non-remitted acute depressed
patients after 12 weeks antidepressant treatment. To evaluate
the association between the slope of the HAM-D24 curve and
BOLD responses, a linear regression analysis was performed
in SPM12 across the group of currently depressed patients. To
test for significant differences in this association between
remitter and non-remitter, a voxel-wise ANOVA was carried
out [13]. Covariates of non-interest in the model were age, sex,
and stimulation thresholds (difference between pain stimuli
and non-pain stimuli).
All results were corrected applying the family-wise error
rate (FWE) at p< 0.05 voxel-level or cluster-level (vFWE
or cFWE, as indicated below), the latter following p< 0.001
uncorrected voxel-level.
Results
For subject details and clinical outcomes please see Fig. 1,
Table 1 and supplementary results.
Neuroimaging results
Treatment effects ANOVA
Acute depressed subjects exhibited significantly different
activation (i.e., hyperactivation) in the no pain vs. baseline
contrast peaking in the left thalamic pulvinar nuclei, the
ventral posterior nucleus, mammillary body and medial
dorsal nucleus at baseline (F2,9= 14.6, cFWE p= 0.004,
Fig. 1 Subject numbers and outcomes. Numbers of all study subjects
are given on the left side. * Early discontinuation reasons are listed at
Table S3 in supplemental material. **Numbers correspond to final
dataset, reasons for exclusion from data-analyses are given in
Table S4. Outcomes after 12 week (wk)-flexible dose antidepressant
treatment with escitalopram, venlafaxine, and mirtazapine are pre-
sented on the right side. Responder are defined by 50% Hamilton
Depression Rating Scale (HAM-D24) reduction to baseline or more,
remitter by HAM-D24< 8. Percentages represent reduction of
HAM-D24
748 C. Kraus et al.
see Fig. 2, Figure S4 and for statistics Table S2). Compared
to rMD (t= 4.3, cFWE p= 0.019) and HC (t= 5.4, cFWE
p= 0.001) hyperactivity in aMD was reduced to values of
HCs at baseline after 12 weeks of treatment. An additional
significant cluster was obtained in the right superior occi-
pital cortex/cuneus (F2,9= 9.4, df= 2/9, cFWE p= 0.003).
A similar pattern, which did not survive statistical correc-
tion in the F-test was observed in the midcingulate cortex.
Here, significantly elevated activation in aMD, which
diminished at fMRI-2 with most difference to rMD was
observed (t= 4.8, cFWE p< 0.001). Additionally, rMD
subjects exhibited higher signal difference between the two
scans in the bilateral precuneus, the occipital cortex and the
anterior lobe of the cerebellum (see Table S2). To exclude
that the effects are solely driven by variability in the healthy
control group, we also tested for significant differences only
for the aMD group. We observed significantly reduced
neuronal activation in the pulvinar and middle cingulate
cortex at uncorrected levels (p< 0.001). There was no sta-
tistical difference in the rmANOVA between rMD subjects
and HC (all p> 0.001) in the no pain vs. baseline contrast.
All other tested contrast combination yielded negative
results (see supplementary results).
Dynamic response regression
The whole-brain regression analysis in aMD patients
with speed of transition values b yielded a significant
negative correlation between dynamic HAM-D24 reduc-
tion and perigenual anterior cingulate (pgACC) and
medial prefrontal cortex (mPFC) activation (t= 4.9,
cFWE p < 0.001, see Fig. 3). This result was obtained in
Fig. 2 Reversal of thalamic hyperactivity after antidepressant treat-
ment. Repeated measures analysis of variance (rmANOVA) compar-
isons between fMRI-1 and fMRI-2 within healthy controls (HC),
remitted depressed patients (rMD), and acute depressed patients
(aMD). Acute patients were treated with escitalopram or venlafaxine
for 12 weeks. a, F-test results depicts elevated activation of thalamic
pulvinar nuclei in acute patients, which reversed to baseline values of
HC after treatment. Activations represents difference in F-test between
fMRI-2 vs. fMRI-1. b, Post-hoc t-tests revealed elevated activity in
midcingulate cortex. Activations represents difference in t-test between
fMRI-2 vs. fMRI-1. Errorbar-plots represent activation values of red
circled-clusters, which survived family-wise error correction (FWE,
cluster-level, p< 0.05). Left is left. Results are depicted at p< 0.001
uncorrected voxel level
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the “unsure no pain” vs. “sure no pain” contrast at fMRI-
2, there were no other significant results surviving
cFWE-correction in other contrasts or fMRI-1. Simply
using the difference between HAM-D24 scores from
MRT-1 and MRT-2 did not result in a significant asso-
ciation with BOLD signal changes (p > 0.001 uncor-
rected). By plotting the activation values of the cluster
against b (corrected for age, sex, and difference in sti-
mulation thresholds), we observed that all but one non-
remitter exhibited higher activation after treatment, i.e.,
in these patients this region was not downregulated after
treatment. However, this was not specific to non-remit-
ter, since activation with remitters overlapped.
The mean β-values of the cluster in the pgACC/mPFC
significantly correlated with escitalopram (r= 0.77, p=
0.005), but not with venlafaxine plasma values (r= 0.05,
p= 0.89, see Figure S3).
Prediction of remission
Activation in the right temporoparietal junction (TPJ) at
fMRI-1 significantly separated remitter from non-remitter in
the expect vs. unsure stimuli (t= 4.1, cFWE p= 0.005, see
Fig. 4a). This cluster had an accuracy of 58%, sensitivity of
41.6% and specificity of 71.4%. While remitting patients
increased their activation between fMRI-1 and fMRI-2,
non-remitter had a decrease of activation at fMRI-2
(Fig. 4a). The difference between fMRI-1 and fMRI-2,
i.e., effects of treatment between remitter and non-remitter,
was associated with significantly higher activation in the left
orbitofrontal cortex in non-remitter (t= 4.7, vFWE p=
0.034). The cluster is located lateral and inferior to the
cluster obtained by the response regression analysis in all
subjects (accuracy= 54%, sensitivity= 50%, specificity=
57%). Activation plots show that non-remitter exhibited
Fig. 3 Dynamic response to antidepressant treatment. a, Hamilton
Depression Rating Scale (HAM-D24) reduction from baseline visit (v1)
to last visit (v8). fMRI-1 and fMRI-2 were 12 weeks apart. The blue
line represents means, the red dashed line corresponds to the function
in (b). b, HAM-D24 reduction was fitted with a general sigmoid model
with days between visits and HAM-D24 scores was fitted for each
acute depressed (aMD) patient and aligned at 0. Colors of single points
represent individual patients. c, d The sigmoid function’s b (i.e., the
slope of the HAM-D24 reduction) was used in a regression model and
yielded a significant negative correlation (p< 0.001, FWE, cluster-
level) between dynamic HAM-D24 reduction and perigenual cingulate
and medial prefrontal activation at fMRI-2. Non-Remitter (=HAM-
D24>8) exhibited higher activation after treatment. Activations repre-
sents t-tests between remitter and non-remitter at fMRI-2. * represents
Pearson correlation coefficient at p< 0.05
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higher baseline activation and increased orbitofrontal
activity at fMRI-2 in comparison to remitting patients
(Fig. 4b). An ANOVA (time point× group) between
remitting and non-remitting MD without the sigmoid model
did not yield significant results (all p> 0.001, uncorr.).
Discussion
In this 12-week, open-label, antidepressant fMRI study we
identified reduction of elevated baseline thalamic activity in
the pulvinar and medial thalamus as significant anti-
depressant treatment effect. These data indicate that anti-
depressant treatment reverses elevated activity in regions of
a major thalamocortical network with strong connections to
the limbic system [14]. Furthermore, optimized detection of
response and remission was achieved by mapping the
dynamic speed of individual treatment response with a
sigmoid function. Thereby, aberrant frontal and anterior
cingulate activity were confirmed as important correlates of
antidepressant response [6, 15–17]. Finally, we detected
that remission was associated with higher pretreatment TPJ
activity. Together, these results speak for reversal of
hyperactivity in regions within salient and attention net-
works as an important antidepressant effect.
Our data are not in accordance with those resulting
from a prior pain fMRI study [10]. It is striking that the
main results were obtained in the no-pain vs. baseline
condition, even though pain yielded expected activations
(Figure S2). Heterogeneity in the depression group with
mixed antidepressant treatments at fMRI-2 or a ceiling-
effect at 7 T, which might not be present in lower field
strengths during physiologically stronger pain-stimuli,
could explain missing results in the pain vs. no-pain con-
trasts. Between group heterogeneity or measurement
time points might not be the main driver of the pulvinar
result, since pulvinar changes were detected in aMD only as
well. Moreover, these studies differ in regard to the field
strengths used, treatment regimens, and comparison groups.
Even though 7 T might exhibit superiority for fMRI-
statistics for most of the brain regions [11] and provide
increased spatial specificity [18], this study in concert with
Fig. 4 Non-remitter failed to
upregulate temporoparietal
junction after treatment . a,
Acute depressed patients who
remitted (aMDDrem) after
12 weeks antidepressant
treatment had significantly more
activity at fMRI-2 in the right
temporoparietal junction in the
expect vs. unsure contrast
(asterisk in a represents p=
0.005, FWE cluster-level).
Remission was defined
conservatively by HAM-D24<8.
Activation represents t-tests
between remitter and non-
remitter at fMRI-2. b, Non-
remitter exhibited significantly
increased activity between
fMRI-1 and fMRI-2 in the no
pain contrast (**represents p=
0.034, FWE voxel-level).
Activation represents t-tests
between remitter and non-
remitter between fMRI-2 and
fMRI-1
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others show that advantages in group discrimination over
lower field strengths might be negligable [19]. For
response-prediction markers research, multimodal approa-
ches [20] and machine learning analyses [21] might be more
valuable than higher field strengths. For future applications
of 7 T fMRI in depression research, determination of
potential confounders such as physiological noise will be
particularly important. Increases in signal strength come at
the cost of increased physiological noise, whereby regions
such as the orbitofrontal cortex with proximal air-tissue
boundaries are at risk.
Nevertheless, these results match studies reporting
altered pulvinar function in MD and highlight pulvinar and
thalamic alterations in the pathophysiologic model of
depression. Increased pulvinar BOLD-signals and glucose
metabolism in untreated MD are substantiated by three
meta-analyses [22–24] and elevated baseline glucose
metabolism in the pulvinar was demonstrated to be reduced
with remission [25]. Our study adds that increased pulvinar
BOLD-signal at baseline was reduced after treatment.
Thalamocortical coupling is altered in depression and
antidepressant therapy targets this connection [26–28].
Table 1 Demographic and
clinical characteristics (analyzed
sample)
Subjects HC rMD aMD p
n 33 36 26
Sex (f/m) 20/13 23/13 19/7 0.592a
Age (y) 26.6± 6.8 28.5± 8.2 30.4± 9.7 0.215b
Age of onset (y) – 22.8± 6.7 21.6± 9.2 0.284c
Number of episodes (n) – 1.7± 1.4 3.2± 1.6 <0.001c
Duration of disease (y) – 5.8± 4.8 9.5± 8.8 0.02c
Current episode/last episode rMD (m) – 9.1± 6 6.8± 12.1 0.128c
Previous medication (unclear/yes/no)d 5/17/13 0/14/12
PT during study (unclear/yes/no) – 2/4/28 4/3/19
PT before study (unclear/yes/no) – 8/20/6 3/9/13
Handedness (r/l) 32/1 34/1 25/1
Scales Pretreatment Posttreatment
HAM-D24 – 2.3± 2.5 27.3± 6.4 8.3± 5.9
HAM-A – 2.5± 2.4 20.9± 5.6 6.7± 3.9
BDI – 4.2± 4.6 21.1± 7.2 7.4± 5.7
CGI – 1.7± 0.8 5.3± 0.5 3.1± 1.2
Medication during study
Escitalopram (mg) – – – 13.9± 4.5
Venlafaxine (mg) – – – 98.2± 41.7
Mirtazapine (mg) – – – 30e
Citalopram plasma (ng/ml) – – – 33.7± 27.3
Venlafaxine plasma (ng/ml) – – – 88.4± 59.2
Painful stimulus intensity
fMRI-1 5.6± 5.2 4.5± 3.4 5.1± 2.8 0.567b
fMRI-2 5.6± 6 4.3± 3.7 5.4± 3.7 0.543b
Non-painful intensity
fMRI-1 1.2± 1.1 1.3± 1.1 1.5± 0.8 0.555b
fMRI-2 1.7± 2.2 1.4± 1.1 1.5± 0.9 0.722b
HC healthy control subjects, rMD remitted depressed subjects, aMD acute depressed patients fMRI-1
functional magnetic resonance imaging session one, HAM-D24 Hamilton Depression Rrating Scale (24 item
version), HAM-A Hamilton Anxiety Rating Scale, BDI Beck Depression Index, CGI Clinical Global
Impression scale, f female, m male, y years, m months, r right, l left
ap-value chi-square test
bp-value analysis of variance
cp-value t-test
dfor detiailed medication see supplementary Table S5
eonly one patient
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Antidepressant effects on the pulvinar and the thalamus are
substantiated in other fMRI tasks [29–31]. Moreover, tha-
lamocortical connectivity was altered upon ketamine
administration [32] and transracial magnetic stimulation to
the dorsolateral prefrontal cortex elevated activity in the
pulvinar nuclei [33]. These results corroborate reduction of
pulvinar hyperactivity by antidepressants, which might not
be specific to a pain fMRI paradigm, but a more general
effect of antidepressant efficacy.
In the following we discuss potential consequences of
altered pulvinar function in MD. The pulvinar nuclei
receive the majority of their inputs from the retina and
reciprocal connections with striatal, extrastriatal, parietal,
temporal, frontal, orbital, cingulate cortices, and the
amygdala were described [14, 34]. They provide quick
feedback for behaviorally relevant stimuli [35] and monitor
attention and/or distraction (reviewed by Pessoa et al. [34]).
Irreversible damage to the pulvinar nuclei was associated
with visual neglect but also with post-stroke pain [36, 37],
which could explain why these results were gathered in a
pain-paradigm. Functional changes in the pulvinar, as
demonstrated in our study, might contribute to biased
acquisition and processing of information, which has been
described as important pathophysiological factor in MD
[38]. Altered thalamocortical processing was suggested to
underlie negativity biases [39], hence, our results might be
neurobiological substrates of biased acquisition and retrie-
val of information, though replication with explicit testing
of salience and negativity bias is needed.
The time course of antidepressant response followed a
sigmoid function, which has been previously demonstrated
[40]. With this optimized model of antidepressant response,
we replicated anterior cingulate and ventromedial prefrontal
cortex activity as antidepressant treatment response corre-
late [6, 7, 17, 41]. Without dynamic response modeling, no
results on response and remission were yielded in this
dataset. Elevated pretreatment anterior cingulate activity is
most often reported in resting state or facial emotion tasks
[6]. Furthermore, the time points of measurement might
impact results, since early response might underlie a dif-
ferent neuronal activity as late response [42, 43]. A sigmoid
response indicates that individual patients respond with a
moderate decline of HAM-D values in the beginning, fol-
lowed by at a certain period of faster response and an again
flatter decline at the end of observations. A steeper decline
in the sigmoid function means that the speed of transition
from depression to remission is faster. By describing
response with a sigmoid function better fits to inter-
individual variations in speed of response could be
gained. But first replication in larger datasets should be
performed. Potentially, differential “response constants”
could be then determined for pharmacological and non-
pharmacological antidepressant treatments. These would
decrease the number of required data points and could in
future be applied to independent datasets.
Applying the model of dynamic response by multiple
study visits, we yielded higher baseline activity in the right
temporoparietal junction (TPJ) in remitter. Non-remitter
exhibited a decrease of activation after treatment. The TPJ is
part of the ventral attention network [44] and usually acti-
vated in fMRI studies by reorienting attention to salient
stimuli [45]. The TPJ is involved in controlling theory of
mind-related abilities [46], which were recently shown to be
significantly reduced in MD [47] (although see negative
results e.g., ref. [48]). MD patients exhibit a reduced visual
arousal in the right TPJ [49]. Treatment elevated TPJ-
hypoactivity towards activity levels of healthy controls [50].
These studies corroborate a role of the TPJ in enabling
internal predictions about external sensory events [51],
which might be altered in MD. In our study, remission was
associated with increased baseline TPJ-activity in relation to
levels of activity in non-remitters. Non-remission was
associated with increased activity in the left orbitofrontal
cortex between fMRI-1 and fMRI-2. The orbitofrontal cortex
is prone to susceptibility artifacts, that is why replication of
this result is needed. Both these results were not sensitive
and specific enough to promote TPJ activity as potential
prognostic marker with clinical applicability. While both
regions seem to be affected by MD, future studies could look
closer into their potential as clinical marker. In general,
clinical applicability of task-based fMRI still remains
an unresolved issue. Here, machine learning approaches
were previously demonstrated to yield higher accuracies
with a low minimum sample size [52]. Moreover, resting
state analyses outperformed task-based fMRI in a meta-
analysis comparing diagnostic classification by machine
learning algorithms [21]. Hence, other imaging modalities
and analyses strategies than task-based fMRI and the
general linear model might in future be more profitable in
finding predictive response or remission markers. Never-
theless, we propose that TPJ-activity should be more
frequently investigated in MD, since easy accessibility by
non-invasive therapies such as TMS could provide reward-
ing paradigms.
A few factors must be kept in mind when interpreting
these findings. Test-retest reliability remains an issue for
potential clinical application of fMRI. Several studies with
only fair to moderate ICC values in pain paradigms were
reported [53], while others find slightly better values [54].
Yet, spatial activation patterns [55] and noise [56] appear to
be stable over measuring time-points. Since we detected
significant differences in aMD patients only, we do not
conclude that the pulvinar result is solely driven by het-
erogeneity potentially present between measurements or
groups. Second, we did not correct for potential effects of
psychotherapy, which might be a limiting factor of the
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current study design. However, previous evidence demon-
strated differential effects of remission to psychotherapy in
the anterior insula and the subgenual cingulate [57, 58],
while no effects on the thalamus were demonstrated. The
potential influence in our sample, given low numbers of
current psychotherapy, might be small, but future studies
should control for psychotherapy. A third limitation might
be the lack of placebo control. While all applied anti-
depressants were demonstrated to be superior to placebo
[59, 60], this does not rule out unwanted placebo effects in
this study. Placebo control in fMRI treatment trials is cur-
rently infrequently applied [8, 61, 62]. For translation of
pharmacological fMRI findings to clinic placebo-controlled
validation might be necessary. In the end, generalization of
predictive markers derived from studies as ours to clinical
populations remains very hard, because inclusion and
exclusion criteria constrain the heterogeneity of major
depression in clinical settings.
Conclusion
This antidepressant fMRI treatment study in patients with
MD applying a pain-paradigm revealed elevated activity in
the medial thalamus, especially in the pulvinar nuclei,
which declined after treatment. Thalamic and pulvinar
activity are a major contributor to depression pathophy-
siology. Moreover, we optimized response assessment by
modeling the dynamic speed of response using a sigmoidal
model with fMRI-data and corroborated the importance of
anterior cingulate function in remission. Moreover, our
results hint towards temporoparietal junction activity as a
potential correlate of non-remission, but confirmation is
needed. The main conclusion of this study is that pulvinar
activity has a key function in depression and antidepressant
treatment, while optimized modeling of response and
remission might be a valuable method for future clinical
depression trials.
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